It is likely that this might ascertain a balance between the proangiogenic and antiangiogenic mediators [138,139,141]
Weight Loss Drugs in 2025: New and Effective Options FDA-Approved Weight Loss Medications The weight loss medication landscape has transformed significantly by 2025
Chronic substance use is associated with reduced activity in prefrontal regions involved in executive control and elevated activity in reward-related striatal circuits
Are circulating microRNAs peripheral biomarkers for Alzheimer's disease
A multidimensional precision medicine approach identifies an autism subtype characterized by dyslipidemia
With our cast of characters in place, glucose, insulin, glucagon, GLP-1, GIP, and SGLT2, we can now move into the pharmacological management of diabetes with much more context for why each medication class works the way it does